Extensive versus strategic reading for learning English at Khulna University, Bangladesh

This article reports on a small-scale research study conducted to investigate the comparative utility of extensive reading versus strategic reading for learning English at the undergraduate level in the English Discipline at Khulna University, a public university in south-western Bangladesh. The study is based on the schema theory where background knowledge is the basis of comprehension. A pre-tested questionnaire was used to conduct a survey. Data was collected from 158 respondents, all undergraduate students in the English Department who were selected at random. The results of the study showed that strategic reading is more favorable to students compared to extensive reading for the purpose of learning ESL/EFL. Finally, the results showed that strategic reading was more effective than extensive reading for learning English. The paper concludes with a call for further large-scale studies

Fabrication and physicochemical characterisation of novel pimozide loaded PLGA nanoparticles

Cancer has always been a big concern for human health. There is always an increased need for fabrication of newer drugs or repurposing existing drugs to treat cancer. Apart from being an antipsychotic agent, pimozide has already shown its anticancer activity against various cancers in several studies. The aim of the present study was to fabricate pimozide loaded PLGA nanoparticles and characterise them. Single emulsion and microfluidic techniques were used to prepare nanoparticles. Physicochemical properties such as particle size, shape, surface charge and encapsulation efficiency were investigated. Results showed that the nanoparticles had an average size distribution of 200-300 nm, were spherical in shape and negatively charged. Additionally, a high encapsulation efficiency (50-89%) makes these nanoparticles potential drug delivery systems to target cancer cells

Analgesic and anti-inflammatory effects of Crinum asiaticum leaf alcoholic extract in animal models

This study investigated the analgesic and anti-inflammatory effects of Crinum asiaticum (Amaryllidaceae) leaf ethanolic extract. Analgesic effect was investigated in acetic acid induced writhing model and formalin induced licking model in swiss albino mice. Anti-inflammatory effect was conducted in carrageenan-induced paw edema model of albino rat. Data were analyzed by one-way analysis of variance (ANOVA) followed by post hoc multiple comparison test. In analgesic study, C. asiaticum extract inhibited 42.34±3.20% of acetic acid induced pain at higher dose of 2.0 g/kg body weight. The effect was statistically significant (p<0.001) compared to the positive control, diclofenac sodium (10 mg/kg). The extract reduced the formalin induced pain 22.60±1.39% in early phase and 27.11±0.87% in late phase at the same dose of 2.0 g/kg and the reductions were significant (p<0.01) compared to the positive control morphine (0.5 mg/kg). In a time-dependent inhibition of carrageenan-induced paw edema model, the extract promoted the inhibitions of paw edema 51.60±2.50% at the 1st h and 40.80±0.52% at the 4th h of administration. These inhibitions were also significant (p<0.01) in comparison to those promoted by diclofenac sodium. No mortality was observed in acute toxicity test. The study concludes that C. asiaticum leaf extract has potential analgesic and anti-inflammatory effects to be recorded as plant-derived complementary medicine.Keywords: Crinum asiaticum, anti-inflammatory, analgesic, Carrageenan, formalinAfrican Journal of Biotechnology Vol. 12(2

Analgesic and anti-inflammatory properties of Argyreia argentea methanol extract in animal model

AbstractAnalgesic effect of Argyreia argentea methanol extract was assessed by acetic acid and formalin induced pain in Swiss albino mice. The extract at doses of 1.0, 1.5 and 2.0 g/kg produced an inhibition of 12.66, 16.04 & 23.60% in acetic acid induced pain and 19.3, 24.5 & 31.0% in formalin induced pain. The anti-inflammatory activity of the same extract was estimated volumetrically by measuring the mean increase in hind paw volume of carrageenan-induced Wistar albino rat with plethysmometer. Oral administration of the extract at doses of 1.0, 1.5 and 2.0 g/kg showed a time-dependent (1st, 2nd, 3rd and 4th hour) response in reduction of inflammation where the highest inhibition 25.0, 36.36 and 44.0%, were recorded at the 4th hour of treatment. Diclofenac sodium (40 mg/kg) has been administrated as a positive control in the inhibition of acetic acid and formalin induced pain as well as in carrageenan-induced paw edema. The results demonstrate that the extract could be a new and potential source of anti-inflammatory and analgesic drug

Pharmacological studies on the antinociceptive, anxiolytic and antidepressant activity of Tinospora crispa

Pharmacological studies were performed in mice on the methanol extract of Tinospora crispa (TC), and of its hexane (HF) and chloroform (CF) fractions. Significant antinociceptive activity was observed for TC, HF, and CF in the acetic acid-induced writhing and formalin-induced paw licking tests. Anxiolytic and antidepressant activity were assessed using the open field, hole board, and elevated plus maze (EPM) tests. TC, HF, and CF demonstrated a significant decrease in spontaneous locomotor activity. They also showed an increase in the number of head-dippings in the hole board test, suggesting decreased fearfulness. TC, and most of its fractions, showed a significant increase of the time spent in the opened arm of the EPM, indicating reduced anxiety. A computational study (PASS prediction, molecular docking and ADME/T analyses) was performed to identify the phytochemicals responsible for activity. Syringin and secoisolariciresinol, displayed a strong predictive binding affinity towards the cyclooxygenase COX-1 and COX-2 enzymes and the KcsA potassium channel while rumphioside B showed the highest predicted binding affinity towards the human serotonin receptor. This provided some support to explain the observed in-vivo antinociceptive, anxiolytic and antidepressant effects and the traditional use of T. crispa as a remedy for pain

Virtual screening of bioactive anti-SARS-CoV natural products and identification of 3β,12-diacetoxyabieta-6,8,11,13-tetraene as a potential inhibitor of SARS-CoV-2 virus and its infection related pathways by MD simulation and network pharmacology

Since the first prevalence of COVID-19 in 2019, it still remains the most devastating pandemic throughout the world. The current research aimed to find potential natural products to inhibit the novel coronavirus and associated infection by MD simulation and network pharmacology approach. Molecular docking was performed for 39 natural products having potent anti-SARS-CoV activity. Five natural products showed high binding interaction with the viral main protease for the SARS-CoV-2 virus, where 3β,12-diacetoxyabieta-6,8,11,13 tetraene showed stable binding in MD simulation until 100 ns. Both 3β,12-diacetoxyabieta-6,8,11,13 tetraene and tomentin A targeted 11 common genes that are related to COVID-19 and interact with each other. Gene ontology development analysis further showed that all these 11 genes are attached to various biological processes. The KEGG pathway analysis also showed that the proteins that are targeted by 3β,12-diacetoxyabieta-6,8,11,13 tetraene and tomentin A are associated with multiple pathways related to COVID-19 infection. Furthermore, the ADMET and MDS studies reveals 3β,12-diacetoxyabieta-6,8,11,13 as the best-suited compound for oral drug delivery

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation